Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373217 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase 2 study, sponsored by Craig L Slingluff, Jr.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00373217 is a Phase 2 study that was terminated before completion, run by Craig L Slingluff, Jr. The registered enrollment target is 6 participants.
The verdict
NCT00373217, a Phase 2 study, was terminated before completion, sponsored by Craig L Slingluff, Jr.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving vaccine therapy together with paclitaxel and carboplatin works in treating patients who are undergoing surgery for stage III or stage IV ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- PROCEDURE conventional surgery
- BIOLOGICAL tetanus toxoid helper peptide
- BIOLOGICAL MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-04-13 |
| Est. Completion | 2008-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373217
The ClinicalTrials.gov registry entry for NCT00373217 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00373217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373217 about?
NCT00373217 is a clinical study titled "Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer". RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Gi...
What is the current status of trial NCT00373217?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2006-04-13. Estimated completion is 2008-02-07.
What interventions are being tested in trial NCT00373217?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), conventional surgery (PROCEDURE), tetanus toxoid helper peptide (BIOLOGICAL), MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00373217?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.